15 research outputs found
Genetics of channelopathies associated with sudden cardiac death
Recent technological advances in cardiology have resulted in new guidelines for the diagnosis,
treatment and prevention of diseases. Despite these improvements, sudden death remains one of the
main challenges to clinicians because the majority of diseases associated with sudden cardiac death
are characterized by incomplete penetrance and variable expressivity. Hence, patients may be unaware
of their illness, and physical activity can be the trigger for syncope as first symptom of the disease.
Most common causes of sudden cardiac death are congenital alterations and structural heart diseases,
although a significant number remain unexplained after comprehensive autopsy. In these unresolved
cases, channelopathies are considered the first potential cause of death. Since all these diseases are of
genetic origin, family members could be at risk, despite being asymptomatic. Genetics has also
benefited from technological advances, and genetic testing has been incorporated into the sudden
death field, identifying the cause in clinically affected patients, asymptomatic family members and
post-mortem cases without conclusive diagnosis. This review focuses on recent advances in the
genetics of channelopathies associated with sudden cardiac deat
Determining the Pathogenicity of Genetic Variants Associated with Cardiac Channelopathies
Advancements in genetic screening have generated massive amounts of data on genetic variation; however, a
lack of clear pathogenic stratification has left most variants classified as being of unknown significance. This
is a critical limitation for translating genetic data into clinical practice. Genetic screening is currently
recommended in the guidelines for diagnosis and treatment of cardiac channelopathies, which are major
contributors to sudden cardiac death in young people. We propose to characterize the pathogenicity of
genetic variants associated with cardiac channelopathies using a stratified scoring system. The development
of this system was considered by using all of the tools currently available to define pathogenicity. The use of
this scoring system could help clinicians to understand the limitations of genetic associations with a disease,
and help them better define the role that genetics can have in their clinical routin
Familial Dilated Cardiomyopathy Caused by a Novel Frameshift in the BAG3 Gene
Dilated cardiomyopathy, a major cause of chronic heart failure and cardiac transplantation,
is characterized by left ventricular or biventricular heart dilatation. In nearly 50% of cases
the pathology is inherited, and more than 60 genes have been reported as disease-causing.
However, in 30% of familial cases the mutation remains unidentified even after comprehensive
genetic analysis. This study clinically and genetically assessed a large Spanish family
affected by dilated cardiomyopathy to search for novel variations.
Methods and Results
Our study included a total of 100 family members. Clinical assessment was performed in
alive, and genetic analysis was also performed in alive and 1 deceased relative. Genetic
screening included resequencing of 55 genes associated with sudden cardiac death, and
Sanger sequencing of main disease-associated genes. Genetic analysis identified a frameshift
variation in BAG3 (p.H243Tfr*64) in 32 patients. Genotype-phenotype correlation identified
substantial heterogeneity in disease expression. Of 32 genetic carriers (one
deceased), 21 relatives were clinically affected, and 10 were asymptomatic. Seventeen of
the symptomatic genetic carriers exhibited proto-diastolic septal knock by echocardiographic
assessment.
Conclusions
We report p.H243Tfr*64_BAG3 as a novel pathogenic variation responsible for familial
dilated cardiomyopathy. This variation correlates with a more severe phenotype of the disease,
mainly in younger individuals. Genetic analysis in families, even asymptomatic individuals,
enables early identification of individuals at risk and allows implementation of
preventive measure
Una nova manera de transmetre la neurociència a la Facultat de Medicina de la UdG: integració de la informació i implicació de l'estudiant
L’experiència que presentem és el disseny de l’assignatura 'Introducció a l'estudi de la Medicina. Estudi de l'estructura i funció del cos humà 4'. Aquest Mòdul, que a partir d’ara ens referirem a ell com a Mòdul de Neurociència, es cursa durant el segon any del grau de Medicina de la Universitat de Girona i té per objectiu principal que l’estudiant assoleixi un coneixement bà sic els aspectes estructurals, cel·lulars, moleculars i funcionals dels mecanismes que regeixen el funcionament del sistema nerviós i dels sentits, que li permetin comprendre més endavant els fonaments biològics de la patologia i de la terapèutica, i és per això que hi participen les à rees de coneixement d’Anatomia, Histologia i Fisiologia. Vam considerar que per arribar al coneixement calia assolir dos aspectes: saber i explica
Stop-Gain Mutations in PKP2 Are Associated with a Later Age of Onset of Arrhythmogenic Right Ventricular Cardiomyopathy
Background
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a cardiac disease characterized by the presence of fibrofatty replacement of the right ventricular myocardium, which may cause ventricular arrhythmias and sudden cardiac death. Pathogenic mutations in several genes encoding mainly desmosomal proteins have been reported. Our aim is to perform genotype-phenotype correlations to establish the diagnostic value of genetics and to assess the role of mutation type in age-related penetrance in ARVC.
Methods and Results
Thirty unrelated Spanish patients underwent a complete clinical evaluation. They all were screened for PKP2, DSG2, DSC2, DSP, JUP and TMEM43 genes. A total of 70 relatives of four families were also studied. The 30 patients fulfilled definite disease diagnostic criteria. Genetic analysis revealed a pathogenic mutation in 19 patients (13 in PKP2, 3 in DSG2, 2 in DSP, and 1 in DSC2). Nine of these mutations created a truncated protein due to the generation of a stop codon. Familial assessment revealed 28 genetic carriers among family members. Stop-gain mutations were associated to a later age of onset of ARVC, without differences in the severity of the pathology.
Conclusions
Familial genetic analysis helps to identify the cause responsible for the pathology. In discrepancy with previous studies, the presence of a truncating protein does not confer a worse severity. This information could suggest that truncating proteins may be compensated by the normal allele and that missense mutations may act as poison peptide
Identification of genetic alterations, as causative genetic defects in long qt syndrome, using next generation sequencing technology
Background: Long QT Syndrome is an inherited channelopathy leading to sudden cardiac death due to ventricular arrhythmias. Despite that several genes have been associated with the disease, nearly 20% of cases remain without an identified genetic cause. Other genetic alterations such as copy number variations have been recently related to Long QT Syndrome. Our aim was to take advantage of current genetic technologies in a family affected by Long QT Syndrome in order to identify the cause of the disease. Methods: Complete clinical evaluation was performed in all family members. In the index case, a Next Generation Sequencing custom-built panel, including 55 sudden cardiac death-related genes, was used both for detection of sequence and copy number variants. Next Generation Sequencing variants were confirmed by Sanger method. Copy number variations variants were confirmed by Multiplex Ligation dependent Probe Amplification method and at the mRNA level. Confirmed variants and copy number variations identified in the index case were also analyzed in relatives. Results: In the index case, Next Generation Sequencing revealed a novel variant in TTN and a large deletion in KCNQ1, involving exons 7 and 8. Both variants were confirmed by alternative techniques. The mother and the brother of the index case were also affected by Long QT Syndrome, and family cosegregation was observed for the KCNQ1 deletion, but not for the TTN variant. Conclusions: Next Generation Sequencing technology allows a comprehensive genetic analysis of arrhythmogenic diseases. We report a copy number variation identified using Next Generation Sequencing analysis in Long QT Syndrome. Clinical and familiar correlation is crucial to elucidate the role of genetic variants identified to distinguish the pathogenic ones from genetic nois
Genetic Analysis of Arrhythmogenic Diseases in the Era of NGS: The Complexity of Clinical Decision-Making in Brugada Syndrome
Background
The use of next-generation sequencing enables a rapid analysis of many genes associated
with sudden cardiac death in diseases like Brugada Syndrome. Genetic variation is identified
and associated with 30–35% of cases of Brugada Syndrome, with nearly 20–25%
attributable to variants in SCN5A, meaning many cases remain undiagnosed genetically.
To evaluate the role of genetic variants in arrhythmogenic diseases and the utility of nextgeneration
sequencing, we applied this technology to resequence 28 main genes associated
with arrhythmogenic disorders.
Materials and Methods
A cohort of 45 clinically diagnosed Brugada Syndrome patients classified as SCN5Anegative
was analyzed using next generation sequencing. Twenty-eight genes were resequenced:
AKAP9, ANK2, CACNA1C, CACNB2, CASQ2, CAV3, DSC2, DSG2, DSP,
GPD1L, HCN4, JUP, KCNE1, KCNE2, KCNE3, KCNH2, KCNJ2, KCNJ5, KCNQ1,
NOS1AP, PKP2, RYR2, SCN1B, SCN3B, SCN4B, SCN5A, SNTA1, and TMEM43. A total of
85 clinically evaluated relatives were also genetically analyzed to ascertain familial
segregation.
Results and Discussion
Twenty-two patients carried 30 rare genetic variants in 12 genes, only 4 of which were previously
associated with Brugada Syndrome. Neither insertion/deletion nor copy number variation
were detected. We identified genetic variants in novel candidate genes potentially
associated to Brugada Syndrome. These include: 4 genetic variations in AKAP9 including a de novo genetic variation in 3 positive cases; 5 genetic variations in ANK2 detected in 4 cases; variations in KCNJ2 together with CASQ2 in 1 case; genetic variations in RYR2,
including a de novo genetic variation and desmosomal proteins encoding genes including
DSG2, DSP and JUP, detected in 3 of the cases. Larger gene panels or whole exome
sequencing should be considered to identify novel genes associated to Brugada Syndrome.
However, application of approaches such as whole exome sequencing would difficult the
interpretation for clinical purposes due to the large amount of data generated. The identification
of these genetic variants opens new perspectives on the implications of genetic background
in the arrhythmogenic substrate for research purposes.
Conclusions
As a paradigm for other arrhythmogenic diseases and for unexplained sudden death, our
data show that clinical genetic diagnosis is justified in a family perspective for confirmation
of genetic causality. In the era of personalized medicine using high-throughput tools, clinical
decision-making is increasingly comple
Clinical and histopathological analysis of the prevalence of cardiac diseases in sudden death: a study based on autopsies
A novel variant in RyR2 causes familiar catecholaminergic polymorphic ventricular tachycardia
Catecholaminergic polymorphic ventricular tachycardia is a rare familial arrhythmogenic disease. It usually occurs in juvenile patients with a structurally normal heart and causes exercise–emotion triggered syncope and sudden cardiac death. The main gene associated with catecholaminergic polymorphic ventricular tachycardia is RyR2, encoding the cardiac ryanodine receptor protein which is involved in calcium homeostasis. After the identification of a 16 year-old man presenting with exercise-induced sudden cardiac death, clinically diagnosed as catecholaminergic polymorphic ventricular tachycardia, we collected the family information and performed a comprehensive genetic analysis using Next Generation Sequencing technology. The initial electrocardiogram in the emergency department revealed ventricular fibrillation. On electrocardiogram monitoring, sinus tachycardia degenerated into bidirectional ventricular and into ventricular fibrillation. Catecholaminergic polymorphic ventricular tachycardia was clinically diagnosed in 5 of the 14 family members evaluated. There were no additional reports of seizures, pregnancy loss, neonatal death, or sudden cardiac death in family members. Genetic analysis of the index case identified only one rare novel variant p.Ile11Ser (c.32T > G) in the RyR2 gene. Subsequent familial analysis identified segregation of the genetic variant with the disease. All current evidence supports that novel p.Ile11Ser variant in the RyR2 gene is a potential disease-causing variant in catecholaminergic polymorphic ventricular tachycardia. To our knowledge, there has been no previous case report of catecholaminergic polymorphic ventricular tachycardia associated to this missense varian
Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs
Blocking the enzyme Fatty Acid Synthase (FASN) leads to apoptosis of HER2-positive breast carcinoma cells. The hypothesis is that blocking FASN, in combination with anti-HER2 signaling agents, would be an effective antitumor strategy in preclinical HER2+ breast cancer models of trastuzumab and lapatinib resistance. We developed and molecularly characterized in vitro HER2+ models of resistance to trastuzumab (SKTR), lapatinib (SKLR) and both (SKLTR). The cellular interactions of combining anti-FASN polyphenolic compounds (EGCG and the synthetic G28UCM) with anti-HER2 signaling drugs (trastuzumab plus pertuzumab and temsirolimus) were analyzed. Tumor growth inhibition after treatment with EGCG, pertuzumab, temsirolimus or the combination was evaluated in two in vivo orthoxenopatients: one derived from a HER2+ patient and another from a patient who relapsed on trastuzumab and lapatinib-based therapy. SKTR, SKLR and SKLTR showed hyperactivation of EGFR and p-ERK1/2 and PI3KCA mutations. Dual-resistant cells (SKLTR) also showed hyperactivation of HER4 and recovered levels of p-AKT compared with mono-resistant cells. mTOR, p-mTOR and FASN expression remained stable in SKTR, SKLR and SKLTR. In vitro, anti-FASN compounds plus pertuzumab showed synergistic interactions in lapatinib- and dual-resistant cells and improved the results of pertuzumab plus trastuzumab co-treatment. FASN inhibitors combined with temsirolimus displayed the strongest synergistic interactions in resistant cells. In vivo, both orthoxenopatients showed strong response to the antitumor activity of the combination of EGCG with pertuzumab or temsirolimus, without signs of toxicity. We showed that the simultaneous blockade of FASN and HER2 pathways is effective in cells and in breast cancer models refractory to anti-HER2 therapie